Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721962 · ClinicalTrials.gov registry record · Phase 1
Treatment of Moderate to Severe Refractory Crohn's Disease
A Phase 1 study of Crohn's Disease, sponsored by Tr1X.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 13
- Study locations
NCT06721962 is a Phase 1 study of Crohn's Disease that is actively recruiting participants, run by Tr1X. The registered enrollment target is 39 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (98% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT06721962, a Phase 1 study of Crohn's Disease, is actively recruiting participants, sponsored by Tr1X.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 13
- Study locations
Study Summary
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL TRX103
Study Locations (13)
California
- University of California, Davis - Sacramento
- University of California, San Francisco - San Francisco
Illinois
- Northwestern - Chicago
- University of Chicago - Chicago
Arizona
- Mayo Clinic Arizona - Scottsdale
Florida
- University of Florida - Gainesville
Iowa
- University of Iowa - Iowa City
Kentucky
- University of Louisville - Louisville
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721962
The ClinicalTrials.gov registry entry for NCT06721962 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Tr1X, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT06721962 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT06721962 about?
NCT06721962 is a clinical study titled "Treatment of Moderate to Severe Refractory Crohn's Disease". This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
What is the current status of trial NCT06721962?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2025-05-05. Estimated completion is 2027-01-30.
What conditions does trial NCT06721962 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT06721962?
The interventions under investigation include: Cyclophosphamide (DRUG), TRX103 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06721962?
This trial is sponsored by Tr1X, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721962 being conducted?
This trial has 13 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Stem Cell Transplantation for Crohn's Disease
RECRUITING · Phase 1
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
-
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.